Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Arthritis Research & Therapy
Published in: Arthritis Research & Therapy 1/2012

Open Access 01-12-2012 | Oral presentation

Research platform for fibromyalgia in Japan

Author: Kusuki Nishioka

Published in: Arthritis Research & Therapy | Special Issue 1/2012

Login to get access

Excerpt

Fibromyalgia (FM) is found worldwide, with an estimated prevalence of 1% to 4% of the general population. In Japan epidemiological surveillance showed number of the patient up to1.66% in population-based studies in 2003, following 2.04% by internet surveillance in 2011. 3,500 Japanese patients with our FM data base, frequent age of onset is 35 to 55 years, estimated prevalence of FM, reaching 40% in woman of age 30 to 50 years old. FM occurs in children and adolescents, although only a few epidemiologic studies. …
Metadata
Title
Research platform for fibromyalgia in Japan
Author
Kusuki Nishioka
Publication date
01-12-2012
Publisher
BioMed Central
Published in
Arthritis Research & Therapy / Issue Special Issue 1/2012
Electronic ISSN: 1478-6362
DOI
https://doi.org/10.1186/ar3560

Other articles of this Special Issue 1/2012

Arthritis Research & Therapy 1/2012 Go to the issue

Oral presentation

Implication of microRNA-140 in osteoarthritis

Oral presentation

Directed induction of chondrogenic cells from mouse dermal fibroblast culture

Poster presentation

Uncoupling protein 3 attenuates generation of reactive oxygen species by interacting with thioredoxin 2 in the mitochondrial intermembrane space

Oral presentation

Microparticles as antigenic targets in human and murine SLE

Oral presentation

Innate and adaptive immune responses to dead and dying cells

Poster presentation

Tks5-dependent formation of circumferential podosomes mediates cell-cell fusion
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits